Myozyme

Myozyme

Manufacturer:

Genzyme
/
Sanofi-Aventis

Distributor:

DKSH
Concise Prescribing Info
Contents
Alglucosidase α
Indications/Uses
Long-term enzyme replacement therapy in patient w/ Pompe disease (acid α-glucosidase deficiency).
Dosage/Direction for Use
20 mg/kg by IV infusion once every 2 wk. Infusion rate: Initially 1 mg/kg/hr, may be gradually increased to 2 mg/kg/hr every 30 min until max 7 mg/kg/hr.
Contraindications
Special Precautions
Infusion associated reactions (IARs). Patient w/ acute illness. Advanced Pompe disease. Monitor patients for signs & symptoms of systemic immune complex-mediated reactions involving skin & other organs during therapy. Perform periodic urinalysis in patients w/ high IgG antibody titres. Discontinue immediately if severe hypersensitivity or anaphylactic reactions occur. Concomitant use w/ immunosuppressive agents. Pregnancy & lactation.
Adverse Reactions
Decreased oxygen saturation; tachycardia; tachypnoea, cough; vomiting; urticaria, rash; flushing; pyrexia. Increased heart rate, BP & body temp; cyanosis; tremor, dizziness, paraesthesia, headache; throat tightness; retching, nausea, diarrhoea; erythema, maculopapular, flushing; macular & papular rash, pruritus, hyperhidrosis; muscle spasms, muscle twitching, myalgia; HTN, pallor, flushing; irritability, chills, chest discomfort, peripheral oedema, local swelling, fatigue, feeling hot; hypersensitivity; agitation.
ATC Classification
A16AB07 - alglucosidase alfa ; Belongs to the class of enzymes. Used in the treatment of alimentary tract and metabolism problems.
Presentation/Packing
Form
Myozyme infusion conc 50 mg
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in